Older women who use bisphosphonate for longer than 5 years may have increased odds of a subtrochanteric or femoral shaft fracture, but absolute risk is low
Methods
The study was a nested 5:1 case-control study, linking prescriptions with hospitalisations, physician service claims and death certifi cates. Women aged 68 years or older who fi lled prescriptions for bisphosphonates at least once over a 6-year period were included. Those with malignant disease in the past 10 years, specifi c bone diseases or secondary causes of osteoporosis (past 5 years) and osteoporosis treatment in the past year were excluded, providing 205 466 women for study.
Cases were defi ned as fi rst ST/FS fracture, excluding fractures treated exclusively with hip replacement and fractures due to vehicle accidents and falls from a height. In a secondary analysis, cases were defi ned as those with a classic osteoporotic fracture (femoral neck or intertrochanteric hip, FN/IT). Another secondary analysis focused on long-term users of bisphosphonates.
Bisphosphonate exposure was categorised as longterm use (≥5 years), intermediate use (between 3 and 5 years), short-term use (100 days to 3 years) and a reference category for 'transient use' (<100 days).
Analysis was conditional logistic regression with adjustment for socioeconomic status (by postcode), key other medications, count of medications, comorbidities, physician claims and existence of a bone mineral measurement. 
Findings

Commentary
Including all ST/FS fractures as the condition of interest in this study means that risks of their occurrence that were identifi ed mark an upper boundary because these fractures include both atypical and osteoporotic fractures. A gradient in risk could suggest a causal relationship. If patients with long-term exposure to bisphosphonates are more likely to fracture then bisphosphonates could be the culprit. But like any association, dose-response relationships can be spurious. For example, patients who take bisphosphonates for a long period of time may do so because they have unusually strong risk factors for fracture. Patients who adhere faithfully to bisphosphonates may also adhere to other medications that could predispose them to fractures. Glucocorticoids and proton pump inhibitors (PPI) were used by a large proportion of patients in this study and in case reports of radiologically adjudicated atypical fractures. PPIs have been linked to increased fracture risk 1 and to attenuation of the effect of alendronate. 2 The fi ndings here were adjusted for baseline PPI and glucocorticoid use, though entering these covariates in a time-dependent Cox proportional hazards analysis might be more informative. Bisphosphonates cause dyspepsia so many patients using PPIs might not have done so at baseline.
The design of this study, a nested case-control study, did not allow calculation of absolute risks and appraisal of competing risks (eg, death) that could have been calculated as information from the full cohort was available. Also, there were large differences between cases and controls. For example, 70% of cases had prior fractures, 67% were 'fallers', and 45% used PPIs; among controls, proportions with these characteristics were 24%, 6% and 36%, respectively. Unmeasured confounders may have been similarly unbalanced. One may compare the known effects of bisphosphonates on hip fractures with data from the current study. Interestingly, although 3 years of treatment in clinical trials reduced the risk of hip fracture by 40-50% in conservative intention-to-treat analyses, 3 4 the current study reports a risk reduction of only 14% after 3-5 years. Some patients in the current study would 
